Dr. Garmey is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
101 College Rd E
G P C Biotech
Princeton, NJ 08540Phone+1 609-936-3100
Education & Training
Icahn School of Medicine at Mount SinaiClass of 2001
Certifications & Licensure
NY State Medical License 2005 - 2019
Clinical Trials
- CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC) Start of enrollment: 2014 Jul 01
Publications & Presentations
PubMed
- 34 citationsEfficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-II...Stephen M. Keefe, Jean H. Hoffman-Censits, Roger B. Cohen, Ronac Mamtani, Daniel F. Heitjan
Annals of Oncology. 2016-08-01 - 65 citationsTranslational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian CancerElizabeth Pham, Michael J. Birrer, Scott Eliasof, Edward Graeme Garmey, Douglas Lazarus
Clinical Cancer Research. 2015-02-15 - 172 citationsPhase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic StudiesTimothy A. Yap, David Olmos, Andre T. Brunetto, Nina Tunariu, Jorge Barriuso
Journal of Clinical Oncology. 2011-04-01
Press Mentions
Chutes & Ladders—Novartis Brings in New CEO to Clean up Korean BranchAugust 24th, 2018- Sensei Brings on New CMO as It Eyes Phase 2 Immuno-Oncology TrialAugust 21st, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
